FOLOTYN®
Peripheral T-Cell Lymphoma
MarketedCommercial (China)
Key Facts
Indication
Peripheral T-Cell Lymphoma
Phase
Marketed
Status
Commercial (China)
Company
About CASI Pharmaceuticals
CASI Pharmaceuticals' mission is to address urgent unmet medical needs in organ transplant rejection and autoimmune diseases through its lead candidate, CID-103. The company has established a commercial footprint in China with products like EVOMELA® and FOLOTYN®, generating revenue to support its R&D. Its strategy hinges on advancing CID-103 as a first-in-class therapy for AMR while leveraging its China commercial platform for sustainable growth. Key achievements include building a dual-region management team and advancing CID-103's preclinical and clinical development.
View full company profile